See more : Osotspa Public Company Limited (OSP.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Lixte Biotechnology Holdings, Inc. (LIXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lixte Biotechnology Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Yara International ASA (YARIY) Income Statement Analysis – Financial Results
- FSD Pharma Inc. (HUGE.CN) Income Statement Analysis – Financial Results
- Seadrill Limited (SDRL.OL) Income Statement Analysis – Financial Results
- Kingwaytek Technology Co., Ltd. (6516.TWO) Income Statement Analysis – Financial Results
- Intercept Energy Services Inc. (IESCF) Income Statement Analysis – Financial Results
Lixte Biotechnology Holdings, Inc. (LIXT)
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 898.10K | 1.35M | 1.74M | 1.22M | 820.91K | 40.70K | 467.26K | 1.30M | 2.09M | 1.12M | 879.89K | 1.01M | 1.33M | 445.54K | 496.52K | 608.73K | 423.83K | 150.10K | 0.00 |
| General & Administrative | 4.19M | 4.96M | 4.98M | 2.01M | 1.67M | 2.10M | 1.34M | 833.78K | 754.44K | 1.29M | 494.96K | 1.09M | 533.45K | 436.14K | 1.05M | 664.20K | 1.23M | 299.42K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.19M | 4.96M | 4.98M | 2.01M | 1.67M | 2.10M | 1.34M | 833.78K | 754.44K | 1.29M | 494.96K | 1.09M | 533.45K | 436.14K | 1.05M | 664.20K | 1.23M | 299.42K | 32.87K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 33.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 74.00K | 0.00 | 0.00 | 0.00 | 0.00 | 128.00 | 615.00 | 592.00 | 462.00 | 0.00 |
| Operating Expenses | 5.09M | 6.31M | 6.72M | 3.27M | 2.49M | 2.14M | 1.81M | 2.13M | 2.85M | 2.40M | 1.37M | 2.11M | 1.87M | 881.68K | 1.55M | 1.27M | 1.66M | 449.98K | 32.87K |
| Cost & Expenses | 5.09M | 6.31M | 6.72M | 3.27M | 2.49M | 2.14M | 1.81M | 2.13M | 2.85M | 2.40M | 1.37M | 2.11M | 1.87M | 881.68K | 1.55M | 1.27M | 1.66M | 449.98K | 32.87K |
| Interest Income | 1.25K | 11.20K | 626.00 | 5.23K | 49.72K | 4.92K | 1.38K | 183.00 | 78.00 | 66.00 | 3.00 | 8.00 | 125.00 | 1.43K | 155.00 | 3.26K | 10.55K | 11.90K | 0.00 |
| Interest Expense | 0.00 | 8.88K | 7.41K | 3.67K | 0.00 | 4.92K | 1.38K | 183.00 | 78.00 | 66.00 | 3.00 | 8.00 | 125.00 | 1.43K | 1.23K | 1.23K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.09M | 6.31M | 6.72M | 3.27M | 2.49M | 2.14M | 1.81M | 2.13M | 205.77K | 363.11K | 3.00 | 8.00 | 199.84K | 0.00 | 128.00 | 615.00 | 592.00 | 462.00 | 0.00 |
| EBITDA | 3.21K | -1.05K | -7.95K | 1.56K | -2.49M | 4.92K | 1.38K | 183.00 | -2.44M | -2.40M | -1.37M | -3.58M | -1.87M | -881.68K | -1.55M | -1.27M | -1.65M | -561.62K | -32.87K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,220.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.09M | -6.31M | -6.72M | -3.27M | -2.49M | -2.14M | -1.81M | -2.13M | -2.65M | -2.40M | -1.37M | -2.11M | -1.87M | -881.68K | -1.55M | -1.27M | -1.66M | -499.98K | -32.87K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,323.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.21K | -1.05K | -7.95K | 1.56K | 49.72K | 4.92K | 1.38K | 183.00 | -205.70K | -363.05K | 3.00 | -1.47M | -199.71K | 1.43K | -1.08K | 2.03K | 10.55K | -38.10K | 0.00 |
| Income Before Tax | -5.09M | -6.31M | -6.73M | -3.26M | -2.44M | -2.13M | -1.81M | -2.13M | -2.85M | -2.77M | -1.37M | -3.58M | -2.07M | -880.25K | -1.55M | -1.27M | -1.65M | -488.08K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,426.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.82K | 6.79K | -1.56K | -49.72K | -9.85K | -1.81K | -2.13K | -78.00 | -66.00 | 0.00 | -8.00 | -125.00 | 0.00 | 0.00 | 0.00 | 0.00 | 38.10K | 32.87K |
| Net Income | -5.09M | -6.30M | -6.74M | -3.26M | -2.39M | -2.13M | -1.81M | -2.13M | -2.85M | -2.77M | -1.37M | -3.58M | -2.07M | -880.25K | -1.55M | -1.27M | -1.65M | -488.08K | -32.87K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,426.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.66 | -39.85 | -5.00 | -2.89 | -2.14 | -2.18 | -1.94 | -2.68 | -3.66 | -3.74 | -1.98 | -5.52 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.66 | -39.85 | -5.00 | -2.89 | -2.14 | -2.18 | -1.94 | -2.68 | -3.66 | -3.74 | -1.98 | -5.51 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 1.91M | 158.20K | 1.35M | 1.13M | 1.12M | 979.94K | 930.00K | 797.00K | 779.00K | 740.00K | 693.00K | 649.00K | 586.16M | 578.94M | 488.64M | 465.41M | 445.13M | 379.17M | 45.00M |
| Weighted Avg Shares Out (Dil) | 1.92M | 158.20K | 1.35M | 1.13M | 1.12M | 979.94K | 930.29K | 797.93K | 779.89K | 740.09K | 693.05K | 649.76K | 586.16M | 578.94M | 488.64M | 465.41M | 445.13M | 379.17M | 45.00M |
How to Sustainably Invest in Penny Stocks
Why Is Lixte Biotech (LIXT) Stock Down 29% Today?
Can Trading Penny Stocks Be a Full Time Job?
LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference
Short Squeeze Stocks: RDBX, MDVL and 3 Others Experts Think Are Ready to Pop
Trending Penny Stocks to Watch As the First Week of May Ends
Short Squeeze Stocks: HCDI, ZYME and 3 Others Experts Think Are Ready to Pop
5 Short Squeeze Candidates To Watch This Week: Aterian, Harbor Custom Development Remain At The Top, Veru Joins
Penny Stocks to Buy For Your Watchlist Next Week
WestPark Capital Announces Completion of $5.8 Million Registered Direct Offering Priced At-The-Market for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)
Source: https://incomestatements.info
Category: Stock Reports